Barclays initiated coverage of Surgery Partners with an Equal Weight rating and $35 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SGRY:
- Surgery Partners price target lowered to $42 from $43 at Citi
- Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2023 Results; Sets 2024 Guidance
- Surgery Partners sees 2024 revenue greater than $3B, consensus $2.99B
- Surgery Partners reports Q4 adjusted EPS 44c, consensus 38c
- Is SGRY a Buy, Before Earnings?